Topics

Safety, Efficiency of Pembrolizumab Monotherapy in Geriatric PD-L1+ NSCLC

20:00 EDT 15 Oct 2019 | Cancer Networks

A pooled analysis of safety, efficacy of pembrolizumab in patients 75+ years of age with PD-L1+ NSCLC

Original Article: Safety, Efficiency of Pembrolizumab Monotherapy in Geriatric PD-L1+ NSCLC

NEXT ARTICLE

More From BioPortfolio on "Safety, Efficiency of Pembrolizumab Monotherapy in Geriatric PD-L1+ NSCLC"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...